What changed at SWB in June, and what the company will not say about it
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
Recent work
356 piecesWhat changed at SSA in June, and what the company will not say about it
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
What a 28% rise in coupling-reagent prices does to a 10 mg vial
Follow the resin, not the catalogue.
The imaging substudy is an afterthought in the protocol and the centrepiece of the debate
The composition data comes from imaging substudies enrolling a few score participants at selected sites. It is the best evidence available and it is thin.
What changed at FGP in June, and what the company will not say about it
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
What changed at SWB in June, and what the company will not say about it
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
What a 9% rise in coupling-reagent prices does to a 2 mg vial
Follow the resin, not the catalogue.
What changed at SGN in June, and what the company will not say about it
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
Why the independent testing market grew a chemistry arm and not a microbiology one
Four independent services underpin confidence in this market. All four are competent at chemistry. Microbiology is a different accreditation, a different facility and a…
What a 37% rise in coupling-reagent prices does to a 20 mg vial
Follow the resin, not the catalogue.
What a 15% rise in coupling-reagent prices does to a 5 mg vial
Follow the resin, not the catalogue.
What changed at WXT in May, and what the company will not say about it
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
Sterility is not a percentage, which is the whole difficulty
Purity, content, identity, sterility and endotoxin are five separate determinations. A single sheet of paper carrying one of them is not evidence about the other four.
What a 26% rise in coupling-reagent prices does to a 20 mg vial
Follow the resin, not the catalogue.
What changed at QST in May, and what the company will not say about it
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
What changed at QST in May, and what the company will not say about it
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
What changed at WXT in May, and what the company will not say about it
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
The pyrogen question has a price, and it is not the price of a purity run
The absence of microbiological capability in this market is a commercial fact with a straightforward explanation, and it is worth understanding before blaming anybody for it.
What a 37% rise in coupling-reagent prices does to a 5 mg vial
Follow the resin, not the catalogue.
What changed at SWB in May, and what the company will not say about it
Documentation practice is the only part of vendor quality a buyer can assess before purchase.